Protara Therapeutics plans BLA for TARA-002 in LMs by 2H 2027; reports $177M cash and runway into 2028.
TARA sits 86% above its 52-week low of $2.77.
Summary
Protara Therapeutics reported Q1 2026 financial results, revealing a robust $177.4 million cash position expected to fund operations into 2028, alongside plans to submit a Biologics License Application for TARA-002 in LMs by late 2027.
Key Events · Product Development and Regulatory · TARA
-
BLA Submission Timeline for TARA-002 in LMs
The company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in the second half of 2027, a significant regulatory step following positive engagement with the FDA.
-
Strong Cash Position and Runway
Protara reported $177.4 million in unrestricted cash, cash equivalents, and marketable debt securities as of March 31, 2026, which is expected to fund planned operations and milestones into 2028.
-
Clinical Trial Progress for TARA-002 in NMIBC
The company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial and initiate the ADVANCED-3 registrational trial in BCG-Naïve patients, both in the second half of 2026.
-
Upcoming Data Presentations and Investor Event
Protara will present updated safety and durability data for TARA-002 in LMs at the ISSVA World Congress and 12-month data for TARA-002 in NMIBC at the AUA Annual Meeting, both in May 2026. An investor webinar on the LMs program is scheduled for May 19, 2026.
Analysis · TARA · Life Sciences
Protara Therapeutics announced its Q1 2026 financial results, highlighting a strong cash position of $177.4 million, which is expected to fund operations into 2028. This provides significant financial stability for the clinical-stage biotech. The company also outlined a key regulatory milestone, intending to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in the second half of 2027. Additionally, Protara provided updates on its NMIBC and IV Choline Chloride programs, with several clinical trial milestones and data presentations anticipated in the coming months.
At the time of this filing, TARA was trading at $5.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $283.6M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.